CLVS Clovis Oncology, Inc. Stock Quote

CLVS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.82	Insider Own	0.40%	Shs Outstand	144.62M	Perf Week	-14.24%
Market Cap	44.23M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	-7.52%	Shs Float	142.87M	Perf Month	-68.99%
Income	-251.90M	PEG	-	EPS next Q	-0.31	Inst Own	25.90%	Short Float / Ratio	19.61% / 6.87	Perf Quarter	-73.74%
Sales	133.00M	P/S	0.33	EPS this Y	47.70%	Inst Trans	-14.77%	Short Interest	28.02M	Perf Half Y	-56.60%
Book/sh	-2.89	P/B	-	EPS next Y	51.60%	ROA	-60.60%	Target Price	-	Perf Year	-89.44%
Cash/sh	0.38	P/C	0.76	EPS next 5Y	-	ROE	73.70%	52W Range	0.23 - 3.32	Perf YTD	-89.24%
Dividend	-	P/FCF	-	EPS past 5Y	24.10%	ROI	-67.70%	52W High	-92.44%	Beta	0.21
Dividend %	-	Quick Ratio	0.10	Sales past 5Y	353.00%	Gross Margin	72.20%	52W Low	10.62%	ATR	0.07
Employees	413	Current Ratio	0.10	Sales Q/Q	-19.00%	Oper. Margin	-	RSI (14)	26.30	Volatility	11.71% 15.23%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	30.40%	Profit Margin	-	Rel Volume	1.18	Prev Close	0.29
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	4.08M	Price	0.25
Recom	3.50	SMA20	-36.54%	SMA50	-69.21%	SMA200	-81.74%	Volume	2,924,127	Change	-13.86%

May-06-22

Downgrade

H.C. Wainwright

Buy → Neutral

May-18-20

Reiterated

H.C. Wainwright

Buy

$29 → $33

Apr-27-20

Downgrade

SVB Leerink

Mkt Perform → Underperform

Apr-09-20

Downgrade

BofA/Merrill

Neutral → Underperform

Jan-08-20

Reiterated

H.C. Wainwright

Buy

$36 → $27

Nov-19-19

Downgrade

Evercore ISI

Outperform → In-line

Sep-24-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

$22 → $10

Aug-13-19

Downgrade

BofA/Merrill

Buy → Neutral

Aug-02-19

Downgrade

Guggenheim

Buy → Neutral

May-29-19

Downgrade

Goldman

Neutral → Sell

Show Previous Ratings

Nov-25-22 12:34PM	Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why Zacks
Nov-21-22 09:35AM	Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS) Zacks
Nov-18-22 01:11PM	7 Stocks to Sell Right Now and 1 to Buy InvestorPlace
Nov-11-22 05:33AM	Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag Simply Wall St. +6.85%
Nov-10-22 10:46AM	Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing Zacks
12:37PM	Loading…
Nov-09-22 12:37PM	Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023 MarketWatch -71.62%
11:11AM	Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms Benzinga
09:55AM	Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:44AM	UPDATE 1-Clovis Oncology flags possible bankruptcy in 'very near term' Reuters
Oct-27-22 05:05PM	Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat Business Wire
10:03AM	Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-26-22 10:02AM	Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-17-22 03:45AM	Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress Business Wire +8.41%
Oct-03-22 01:35PM	Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings Benzinga
07:00AM	TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations Business Wire
11:29AM	Loading…
Sep-21-22 11:29AM	Clovis, Isotopia Ink Clinical Supply Pact For Lutetium-177 Used In Its Targeted Cancer Radiation Therapy Benzinga
08:00AM	Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement Business Wire
Sep-14-22 01:09PM	Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer Zacks -6.71%
Sep-13-22 08:00AM	Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer Business Wire
Sep-12-22 07:09PM	Why Clovis Oncology Zoomed 30% Higher Today Motley Fool +30.43%
09:11AM	Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line Maintenance Benzinga
Sep-11-22 10:30AM	Clovis Oncologys Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups Business Wire
Sep-07-22 11:30AM	Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound? Zacks
Aug-14-22 08:19AM	The Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St.
Aug-08-22 01:37PM	Why Clovis Oncology Stock Is Sinking Today Motley Fool -12.65%
12:42PM	Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss Zacks
09:15AM	Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs Business Wire
Aug-02-22 10:00AM	Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know Zacks +5.96%
Aug-01-22 10:01AM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks -9.58%
08:30AM	Loading…
08:30AM	7 Penny Stocks to Buy Before the Bull Market Returns InvestorPlace
Jul-20-22 06:06PM	CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8 Business Wire
Jul-19-22 03:43PM	Why Clovis Oncology Stock Trounced the Market Today Motley Fool +5.26%
Jul-15-22 09:53AM	Why Clovis Oncology Stock Went Into Retreat Mode This Week Motley Fool
Jul-08-22 03:55PM	Roku stock projected to climb 53% annually, Mastercard pauses LIV player activations Yahoo Finance Video +27.65%
11:36AM	Why Clovis Oncology Stock Is Crushing It Today Motley Fool
Jul-07-22 04:33PM	Why Clovis Oncology Shares Jumped 158.9% in June Motley Fool
12:27PM	Why Clovis Oncology Stock Is Taking a Step Backward Today Motley Fool
07:45AM	FDA's Recommendation Before Clovis Submits Rubraca Application For Ovarian Cancer Benzinga
Jun-21-22 12:18PM	Why Clovis Oncology Stock Is Blasting Off Today Motley Fool +38.98%
Jun-16-22 04:20PM	Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study Zacks -7.45%
Jun-15-22 07:49AM	Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial Benzinga +19.36%
Jun-14-22 02:00PM	Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting Business Wire +15.70%
Jun-10-22 10:23AM	15 Best Penny Stocks To Invest In Insider Monkey -9.14%
Jun-06-22 08:00AM	Clovis Oncologys Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status Business Wire -10.79%
Jun-03-22 11:31AM	Why Is Clovis (CLVS) Down 55.2% Since Last Earnings Report? Zacks +14.39%
Jun-01-22 08:19AM	What Kind Of Shareholders Own Clovis Oncology, Inc. (NASDAQ:CLVS)? Simply Wall St.
May-16-22 08:30AM	2 Biotech Stocks That Could Go Parabolic Motley Fool +6.10%
May-09-22 11:05AM	Alcon (ALC) to Report Q1 Earnings: What's in the Cards? Zacks -17.90%
May-06-22 01:23PM	Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results Zacks -32.56%
07:12AM	Why Clovis Oncology Stock Was Plummeting This Week Motley Fool
May-05-22 10:22AM	Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag Zacks -12.50%
08:00AM	Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference Business Wire
May-04-22 02:21PM	Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss Zacks -20.00%
09:15AM	Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs Business Wire
May-03-22 08:35AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-02-22 12:21PM	Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings? Zacks
10:01AM	DaVita (DVA) to Report Q1 Earnings: What's in the Offing? Zacks
Apr-28-22 08:00AM	Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting Business Wire
Apr-27-22 03:03PM	Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-20-22 08:00AM	Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4 Business Wire
Apr-18-22 04:51PM	Why Clovis Oncology Stock Fell 10.5% on Monday Motley Fool
Apr-08-22 02:54PM	Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition Benzinga
08:00AM	Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022 Business Wire
Apr-04-22 03:11PM	Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study Zacks +8.80%
Mar-31-22 05:06PM	These 10 Stocks Are Skyrocketing Today Insider Monkey +22.42%
04:41PM	Why Clovis Oncology Stock Skyrocketed 80% This Week Motley Fool
09:22AM	Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status Benzinga
08:01AM	Clovis Oncology to seek FDA approval for ovarian cancer drug as a maintenance therapy MarketWatch
06:00AM	Clovis Oncologys Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial Business Wire
Mar-25-22 11:30AM	Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report? Zacks
Mar-16-22 08:00AM	Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 Business Wire
Feb-26-22 06:34AM	Newsflash: Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Revenue Forecasts Simply Wall St.
Feb-25-22 08:00AM	Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting Business Wire
Feb-24-22 02:49PM	Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag Zacks +20.99%
Feb-23-22 08:05AM	Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones Business Wire
Feb-10-22 04:05PM	Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call Business Wire
Jan-19-22 10:15AM	2 Cancer Stocks With Absurdly Low Valuations Motley Fool
Jan-10-22 08:00AM	Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 Business Wire
Jan-03-22 10:07AM	Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? Zacks +15.87%
Dec-09-21 08:00AM	Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit Business Wire -7.91%
Dec-03-21 11:31AM	Why Is Clovis (CLVS) Down 32% Since Last Earnings Report? Zacks -11.25%
Nov-04-21 06:46AM	Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag Zacks
Nov-03-21 09:15AM	Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces Third Quarter 2021 Operating Results Business Wire
07:48AM	Shareholders in Clovis Oncology (NASDAQ:CLVS) are in the red if they invested five years ago Simply Wall St.
Oct-27-21 03:03PM	Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks -5.29%
Oct-20-21 08:00AM	Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3 Business Wire
Oct-19-21 08:00AM	Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement Business Wire
Oct-15-21 09:15AM	Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition Zacks
Oct-07-21 09:00AM	Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286 Business Wire
Sep-29-21 10:00AM	Can These Former Biotech Growth Stocks Regain Their Form? Motley Fool
Sep-20-21 08:00AM	Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program Business Wire -5.58%
Sep-03-21 11:31AM	Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound? Zacks -5.71%
Aug-27-21 11:37AM	Why Clovis Oncology Shares Got a Bump This Week Motley Fool
Aug-24-21 02:00AM	Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland Business Wire
Aug-16-21 04:21PM	Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program Business Wire
Aug-05-21 10:57AM	Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down Zacks
02:34AM	What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)? Simply Wall St.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rolfe Lindsey	See Remarks	Nov 02	Sale	0.98	4,261	4,188	111,419	Nov 03 04:15 PM
MUEHL DANIEL W	See Remarks	Nov 02	Sale	0.98	4,579	4,501	102,271	Nov 03 04:15 PM
Harding Thomas C.	See Remarks	Nov 02	Sale	0.98	63	62	3,801	Nov 03 04:15 PM
Harding Thomas C.	See Remarks	Nov 02	Sale	0.98	1,703	1,674	18,590	Nov 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Nov 02	Sale	0.98	3,681	3,618	290,993	Nov 03 04:15 PM
Gross Paul Edward	See Remarks	Nov 02	Sale	0.98	4,730	4,649	95,840	Nov 03 04:15 PM
Harding Thomas C.	See Remarks	Oct 03	Sale	1.29	6	8	3,683	Oct 04 04:15 PM
MUEHL DANIEL W	See Remarks	Sep 02	Sale	1.20	2,234	2,681	99,161	Sep 06 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Sep 02	Sale	1.20	2,234	2,681	288,919	Sep 06 04:15 PM
Harding Thomas C.	See Remarks	Sep 02	Sale	1.20	172	206	3,674	Sep 06 04:15 PM
Harding Thomas C.	See Remarks	Sep 02	Sale	1.20	1,444	1,733	17,816	Sep 06 04:15 PM
Gross Paul Edward	See Remarks	Sep 02	Sale	1.20	2,308	2,770	92,812	Sep 06 04:15 PM
Rolfe Lindsey	See Remarks	Sep 02	Sale	1.20	2,545	3,054	109,578	Sep 06 04:15 PM
Gross Paul Edward	See Remarks	Aug 02	Sale	1.46	4,807	7,024	87,601	Aug 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Aug 02	Sale	1.46	3,802	5,555	283,565	Aug 03 04:15 PM
Rolfe Lindsey	See Remarks	Aug 02	Sale	1.46	4,330	6,326	104,826	Aug 03 04:15 PM
MUEHL DANIEL W	See Remarks	Aug 02	Sale	1.46	4,654	6,799	93,807	Aug 03 04:16 PM
Harding Thomas C.	See Remarks	Aug 02	Sale	1.46	77	112	3,338	Aug 03 04:15 PM
Harding Thomas C.	See Remarks	Aug 02	Sale	1.46	1,732	2,530	15,481	Aug 03 04:15 PM
Harding Thomas C.	See Remarks	Jul 05	Sale	2.71	7	19	3,234	Jul 06 04:15 PM
Rolfe Lindsey	See Remarks	Jun 02	Sale	0.64	2,650	1,703	103,016	Jun 03 04:15 PM
Harding Thomas C.	See Remarks	Jun 02	Sale	0.64	218	140	3,225	Jun 03 04:15 PM
Harding Thomas C.	See Remarks	Jun 02	Sale	0.64	1,504	966	14,720	Jun 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Jun 02	Sale	0.64	2,327	1,495	281,518	Jun 03 04:15 PM
Gross Paul Edward	See Remarks	Jun 02	Sale	0.64	2,403	1,544	84,615	Jun 03 04:15 PM
MUEHL DANIEL W	See Remarks	Jun 02	Sale	0.64	2,327	1,495	90,737	Jun 03 04:15 PM
MUEHL DANIEL W	See Remarks	May 02	Sale	1.97	4,570	9,002	85,439	May 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	May 02	Sale	1.97	3,733	7,353	276,220	May 03 04:15 PM
Gross Paul Edward	See Remarks	May 02	Sale	1.97	4,570	9,002	79,393	May 03 04:15 PM
Rolfe Lindsey	See Remarks	May 02	Sale	1.97	4,252	8,376	98,327	May 03 04:15 PM
Harding Thomas C.	See Remarks	May 02	Sale	1.97	76	150	2,936	May 03 04:15 PM
Harding Thomas C.	See Remarks	May 02	Sale	1.97	1,700	3,349	12,429	May 03 04:15 PM
Harding Thomas C.	See Remarks	Apr 04	Sale	2.66	7	19	2,831	Apr 05 04:16 PM
Gross Paul Edward	See Remarks	Mar 02	Sale	1.87	10,706	19,977	66,444	Mar 03 04:15 PM
Rolfe Lindsey	See Remarks	Mar 02	Sale	1.87	10,945	20,423	86,817	Mar 03 04:15 PM
MUEHL DANIEL W	See Remarks	Mar 02	Sale	1.87	10,706	19,977	72,490	Mar 03 04:16 PM
Harding Thomas C.	See Remarks	Mar 02	Sale	1.87	880	1,642	1,662	Mar 03 04:15 PM
Harding Thomas C.	See Remarks	Mar 02	Sale	1.87	6,946	12,961	6,850	Mar 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Mar 02	Sale	1.87	10,770	20,097	264,308	Mar 03 04:15 PM
Rolfe Lindsey	See Remarks	Feb 02	Sale	1.94	4,514	8,756	84,357	Feb 03 04:17 PM
MUEHL DANIEL W	See Remarks	Feb 02	Sale	1.94	5,436	10,544	70,045	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Feb 02	Sale	1.94	81	157	1,652	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Feb 02	Sale	1.94	2,037	3,951	6,015	Feb 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Feb 02	Sale	1.94	4,442	8,616	261,802	Feb 03 04:16 PM
Gross Paul Edward	See Remarks	Feb 02	Sale	1.94	5,436	10,544	63,999	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Jan 03	Sale	2.75	7	19	1,551	Jan 04 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience